These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31905896)

  • 1. Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial.
    Hirai H; Higa M; Morimoto T; Sakuma M; Arasaki O; Nomiyama T; Node K; Ueda S; Shimabukuro M
    J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31905896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
    Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
    Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial.
    Morimoto T; Sakuma I; Sakuma M; Tokushige A; Natsuaki M; Asahi T; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    Sci Rep; 2019 Jun; 9(1):8537. PubMed ID: 31189978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus.
    Chiba Y; Yamakawa T; Tsuchiya H; Oba M; Suzuki D; Danno H; Takatsuka Y; Shigematsu H; Kaneshiro M; Terauchi Y
    J Clin Med Res; 2018 Aug; 10(8):648-656. PubMed ID: 29977423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
    Aoki K; Ijima T; Kamiyama H; Kamiko K; Terauchi Y
    Expert Opin Pharmacother; 2015; 16(12):1749-54. PubMed ID: 26098722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
    Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
    Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial.
    Teragawa H; Morimoto T; Fujii Y; Ueda T; Sakuma M; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Ueda S
    Diabetes Metab Syndr Obes; 2020; 13():4993-5001. PubMed ID: 33364803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).
    Masuda D; Kobayashi T; Sairyou M; Hanada H; Ohama T; Koseki M; Nishida M; Maeda N; Kihara S; Minami T; Yanagi K; Sakata Y; Yamashita S
    J Atheroscler Thromb; 2018 Jun; 25(6):512-520. PubMed ID: 29199201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anagliptin Monotherapy for Six Months in Patients With Type 2 Diabetes Mellitus and Hyper-Low-Density Lipoprotein Cholesterolemia Reduces Plasma Levels of Fasting Low-Density Lipoprotein Cholesterol and Lathosterol: A Single-Arm Intervention Trial.
    Ikegami Y; Takenaka Y; Saito D; Shimada A; Inoue I
    J Clin Med Res; 2021 Nov; 13(10-11):502-509. PubMed ID: 34925661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.
    Teragawa H; Morimoto T; Fujii Y; Ueda T; Sakuma M; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Ueda S
    Diabetes Metab Syndr Obes; 2022; 15():685-694. PubMed ID: 35264863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.
    Yano W; Inoue N; Ito S; Itou T; Yasumura M; Yoshinaka Y; Hagita S; Goto M; Nakagawa T; Inoue K; Tanabe S; Kaku K
    J Diabetes Investig; 2017 Mar; 8(2):155-160. PubMed ID: 27860391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus.
    Shigematsu E; Yamakawa T; Kadonosono K; Terauchi Y
    J Clin Med Res; 2014 Oct; 6(5):327-35. PubMed ID: 25110536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sitagliptin on serum lipid levels in patients with type 2 diabetes: a systematic review and meta-analysis.
    Wu LD; Zhou N; Sun JY; Yu H; Wang RX
    J Cardiovasc Med (Hagerstown); 2022 May; 23(5):308-317. PubMed ID: 35486682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
    Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial.
    Iijima T; Aoki K; Kondo Y; Terauchi Y
    J Clin Med Res; 2020 Feb; 12(2):73-78. PubMed ID: 32095176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
    Shimabukuro M; Higa M; Tanaka H; Shimabukuro T; Yamakawa K; Masuzaki H
    Diabet Med; 2011 Jul; 28(7):856-64. PubMed ID: 21244474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.